7th Pharmaron Symposium on Synthetic and Medicinal Chemistry

A group of ten people are standing in front of a large banner that reads "The 7th Pharmaron Symposium on Synthetic and Medicinal Chemistry" in both English and Chinese. Dressed in business attire and standing on an outdoor stage, they discuss topics like genetic toxicology and absolute bioavailability.

Capabilities

Knowledge Center
Symposiums
Synthetic Chemistry
Medicinal Chemistry
Connect with a Scientific Expert

September 16, 2017 l Beijing Headquarters

  • Dr. Markus Follmann, VP, Medicinal Chemistry, Bayer AG, Germany: Discovery of the Soluble Guanylate Cyclase Stimulators Riociguat and Vericiguat 
  • Dr. Andras Horvath, Scientific Director, Johnson & Johnson, Belgium : Development of Simeprevir (TMC435): A Study Case Macrocyclisation on Industrial Scale 
  • Prof. Jinbo Hu, Shanghai Institute of Organic Chemistry (SIOC), China: Developing New Fluorination and Fluoroalkylation Reagents by Tackling the Unique “Fluorine Effects” 
  • Dr. Garry Pairaudeau, Head of Hit Discovery, AstraZeneca, UK: Innovation in Lead Generation at AstraZeneca 
  • Prof. Sarah Reisman, Department of Chemistry, California Institute of Technology, USA : Necessity is the Mother of Invention: Natural Products and the Chemistry they Inspire 
  • Prof. Barry Trost, Stanford University, USA: Cycloadditions via TMM-Pd Intermediates: New Strategies for Asymmetric Induction and Total Synthesis 
  • Dr. Petr Vachal, AVP, Discovery Chemistry, Global Head of Screening, Target and Compound Profiling, MSD, USA: Merck (MSD) Drug Discovery Enabled 
  • Dr. Steven Wittenberger, Distinguished Research Fellow and Senior Director, Process R&D, AbbVie, USA: Process Research and Development for Venetoclax